Medtronic, a global medical technology company dealing in sophisticated diabetes management solutions, has launched the Enlite Sensor for continuous glucose monitoring in over 35 countries.
The Enlite Sensor helps diabetes patients to predict and detect low blood sugar, hypoglycemia, and also achieve improved glucose control. Integrating the device with insulin pump therapy aids diabetes patients to attain even better glucose control. When the sensor is used along with Medtronics’ predictive alerts feature, hypo detection rates as high as 98% can be achieved.
The Enlite Sensor is 69% smaller in size and 38% shorter in length compared to the previous model introduced by Medtronic. It is easier to insert and can be worn on the buttocks and the abdomen.
The company is working with FDA to commercialize the sensor in the U.S. It has already received the CE Mark approval in France.
The Enlite Sensor can be used with Guardian REAL-Time Continuous Glucose Monitoring System, iPro 2, MiniMed Paradigm Veo System and MiniMed Paradigm REAL-Time System.